Physician profile
David Wenz
NPI 1467531590
$1,550.86
in general payments reported to CMS, 2019-2025
9 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.19 · 2020: $28.11 · 2021: $164 · 2022: $161 · 2023: $549 · 2024: $337 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $655.60 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $315.29 | 2022-2025 | Infuse, Biotrue, Miebo |
| Alcon Vision LLC | $217.38 | 2020-2025 | Precision 1, Precision7, Total30 |
| New World Medical,INC. | $124.24 | 2023 | |
| Abbvie INC. | $62.59 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Johnson & Johnson Vision Care, INC. | $58.64 | 2021-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.18 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $45.35 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $16.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.